Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for clearing severe psoriasis skin

NCT ID NCT05730725

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested a new drug called BMS-986322 to see if it could safely reduce the skin plaques and symptoms of moderate-to-severe psoriasis. It involved 109 adults with significant psoriasis coverage and compared the drug's effects to a placebo over 12 weeks. The main goal was to see how many people achieved a 75% or greater improvement in their skin condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0001

    Los Angeles, California, 90045-3606, United States

  • Local Institution - 0002

    Fremont, California, 94538, United States

  • Local Institution - 0003

    Santa Ana, California, 92701-2201, United States

  • Local Institution - 0004

    Beverly, Massachusetts, 01915-1672, United States

  • Local Institution - 0005

    Fountain Valley, California, 92708-3701, United States

  • Local Institution - 0006

    Birmingham, Alabama, 35205-5021, United States

  • Local Institution - 0007

    Portsmouth, New Hampshire, 03801, United States

  • Local Institution - 0008

    Cleveland, Ohio, 44106-1716, United States

  • Local Institution - 0011

    Webster, Texas, 77598, United States

  • Local Institution - 0012

    Encino, California, 91436, United States

  • Local Institution - 0013

    Coral Gables, Florida, 33134-5736, United States

  • Local Institution - 0016

    Los Angeles, California, 90056, United States

  • Local Institution - 0019

    Carlton, Victoria, 3053, Australia

  • Local Institution - 0020

    Hamilton, Ontario, L8L 3C3, Canada

  • Local Institution - 0023

    tabashi City, Tokyo, 1738606, Japan

  • Local Institution - 0024

    Brisbane, Queensland, 4102, Australia

  • Local Institution - 0026

    Nagoya, 467-8602, Japan

  • Local Institution - 0027

    Tsu, 514-8507, Japan

  • Local Institution - 0030

    Toronto, Ontario, M2N 3A6, Canada

  • Local Institution - 0034

    Barrie, Ontario, L4M 7G1, Canada

  • Local Institution - 0041

    London, Ontario, N6A 2C2, Canada

  • Local Institution - 0042

    Itabashi-Ku, 173-8610, Japan

  • Local Institution - 0044

    Clarksville, Indiana, 47129-2201, United States

  • Local Institution - 0045

    Pascoe Vale South, Victoria, 3044, Australia

  • Local Institution - 0046

    Leytonstone, E11 1NR, United Kingdom

  • Local Institution - 0049

    Sapporo, Hokkaido, 064-0807, Japan

  • Local Institution - 0050

    Hinckley, LEC, LE10 2SE, United Kingdom

  • Local Institution - 0051

    Fukuoka, 814-0180, Japan

  • Local Institution - 0055

    Durham, North Carolina, 27713-8507, United States

  • Local Institution - 0056

    Skokie, Illinois, 60077-1049, United States

  • Local Institution - 0057

    Leawood, Kansas, 66211, United States

  • Local Institution - 0058

    Rapid City, South Dakota, 57702-9208, United States

  • Local Institution - 0059

    Dallas, Texas, 75230-5808, United States

  • Local Institution - 0060

    Lee's Summit, Missouri, 64064, United States

  • Local Institution - 0062

    St. John's, Newfoundland and Labrador, A1E 1V4, Canada

Conditions

Explore the condition pages connected to this study.

PSORIASIS